Actively Recruiting
Exploring the Diagnostic Biomarkers of Cognitive Disorders in China
Led by Cuibai Wei，Clinical Professor · Updated on 2024-11-14
3000
Participants Needed
1
Research Sites
571 weeks
Total Duration
On this page
Sponsors
C
Cuibai Wei，Clinical Professor
Lead Sponsor
F
First Hospital of Shijiazhuang City
Collaborating Sponsor
AI-Summary
What this Trial Is About
Dementia is a syndrome characterized by progressive global cognitive impairment that impairs occupational, family, or social functioning. It detrimentally affects personal health and quality of life, imposing significant medical economy, social and psychological burden on the countries and the patients' family. The internationally renowned dementia cohort includes the DIAN that focused on genetics studies, the ADNI cohort featuring imaging and the FINGERS cohort focused on risk factor intervention, etc. Establishing standardized and shared longitudinal follow-up dementia cohorts and clinical database is an essential challenge for constructing dementia cohort in China. Moreover, there is a lack of large-scale prospective longitudinal follow-up cohorts within the Chinese population that cover subjective cognitive decline (SCD) to explore biomarkers with diagnostic and early warning value for different kinds of dementia and pre-dementia stages. The study will rely on the dementia cohort based on Chinese population to explore the biological phenotype characteristics of the pre-dementia stage and different dementia subtypes, and observe the dynamic change rules of the dementia cohort vertically, so as to foster early intervention and improve prognosis for individuals with dementia.
CONDITIONS
Official Title
Exploring the Diagnostic Biomarkers of Cognitive Disorders in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 640 and 6490 years
- Experiencing cognitive decline reported by self or others
- Able to communicate in Chinese
- Patients and their families have provided informed consent
You will not qualify if you...
- Mini-Mental State Examination score less than 10
- Presence of other neurological diseases causing brain dysfunction (e.g., depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus)
- Presence of systemic diseases causing cognitive impairment (e.g., hepatic insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol or drug abuse)
- Unable to cooperate with cognitive examinations
- Contraindications to MRI
- Mental or neurodevelopmental delay
- Refusal to have blood drawn
- Refusal to sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Capital Medical University Xuanwu Hospital
Beijing, China
Actively Recruiting
Research Team
C
Cuibai Wei
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here